ClinicalTrials.gg
RecruitingNCT07790458Updated Aug 27, 2026

Automated Non-Invasive Blood Pressure Study

An observational study in Blood Pressure and Blood Pressure Measurement, sponsored by GE Healthcare. Recruiting at 2 sites in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by GE Healthcare · Observational

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to design and implement methods to make an algorithm to estimate blood pressure changes.

Read the detailed description

Patient monitoring of blood pressure is essential for patient safety in hospitals. Automated non-invasive blood pressure (NIBP) uses data recorded with an SpO2 pulse oximeter to calculate a continuous estimate of blood pressure changes.

The purpose of the study is to design and implement methods to make an algorithm to estimate blood pressure changes.

This study will collect data for development of automated rules and evaluation of their performances in various clinical settings and to develop a larger clinical trial.

02

Conditions studied

  • Blood Pressure
  • Blood Pressure Measurement
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated in Meilahti hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written or have a LDR to provide written informed consent;
  2. Are being cared for in OR, PACU or ICU and are expected to remain in the unit for the duration of the study procedure;
  3. Have an invasive blood pressure measurement as a standard of care; AND
  4. Are 18 years of age or older.

Exclusion criteria

Exclusion Criteria:

  1. Are known to be pregnant;
  2. Are breastfeeding;
  3. Are suffering from infection(s) that require isolation; OR
  4. Have an external heart assistant device.
  5. PI or caring physician decision due to subject health condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    The primary outcome is to collect SpO2 data using Automated Non-Invasive Blood Pressure from subjects in ICU, OR and PACU environment using the investigational system. This data will be used for engineering development purposes.

    Time frame: Up to 24 hours after time of enrollment

Other outcomes

  1. Safety Outcome

    The safety outcome of this study are type and number of AEs, SAEs, and device deficiencies.

    Time frame: 24 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Aug 27, 2026
StartActual
Apr 14, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07790458
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Apr 14, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 27, 2026

Study contacts

Erika Wilkman Principal Invastigator
Contact
erika.wilkman@hus.fi
+35894711

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion